https://www.selleckchem.com/pr....oducts/4-aminobutyri
001). Complete (R resection was achieved in 89% of patients. The median recurrence-free survival was 11 months (95% confidence interval 7.9-14.1). During follow-up, eight (12.7%) patients in the VATS group and 42 (22.3%) patients in the thoracotomy group experienced recurrence (p = 0.98). The median overall survival was 61 months (95% confidence interval 46.1-75.9), and there was no significant difference with regard to the surgical method used (p = 0.34). VATS metastasectomy can be considered in patients with a solitary l
Like
Comment
Share
